Mileutis

Company Overview

Snapshot

Founded in January 2004 by David Javier Iscovich and Jose Iscovich, Mileutis is a bio-pharmaceutical company with 11–50 employees. The company has raised $20M across two funding rounds from two investors. In May 2024, Yotvata Dairy invested in Mileutis to improve milk quality.

Business overview

Mileutis is a bio-pharmaceutical company dedicated to discovering, developing, and commercializing novel, biologically sourced, safe, and residual-free therapies for both animal and human health. The company's core technology revolves around peptides and specific protein fragments that modulate immune responses, enabling the management of infectious and chronic diseases without antibiotics. Mileutis aims to address the global threat of antimicrobial resistance (AMR) by providing antibiotic alternatives. Its lead products, Imilac and Milac, are designed for the management, treatment, and prevention of mastitis in dairy cows, seeking to replace antibiotics in dairy farms, enhance cow well-being, and boost milk yield and productivity for farmers. Mileutis operates within the Health Tech & Life Sciences sector, specifically targeting Pharmaceuticals and Livestock markets globally.

Strategic signal

In May 2024, Yotvata Dairy Farm invested in Mileutis, signaling strong commercial validation and a strategic partnership for the company's antibiotic-alternative solutions. This investment highlights growing industry confidence in Mileutis's approach to improving milk quality and reducing antibiotic use in dairy farming, which is crucial for addressing antimicrobial resistance and enhancing agricultural sustainability.

Company Intelligence Q&A

What is Mileutis's primary focus?

Mileutis is a bio-pharmaceutical company focused on the discovery, development, and commercialization of novel, biologically sourced, safe, and residual-free therapies for animal and human health, particularly aiming to reduce antibiotic use.

What significant investment did Mileutis receive recently?

In May 2024, Yotvata Dairy Farm invested in Mileutis to improve milk quality, indicating a strategic partnership and commercial validation for the company's products.

Which products are Mileutis's lead offerings?

Mileutis's lead products are Imilac and Milac, which are designed to manage, treat, and prevent mastitis in dairy cows.

What was a key finding from Mileutis's clinical trials?

In August 2023, clinical trials demonstrated that Mileutis's antibiotic-free therapy for cows resulted in better milk quality and a dramatic reduction in antibiotic use.